
5.21.17

Section	Prescription Drugs	Effective Date:	April 1, 2021
Subsection:	Antineoplastic Agents	Original Policy Date:	February 28, 2012
Subject:	Erwinaze	Page:	1 of 4

Last Review Date: March 12, 2021

Erwinaze

Description

Erwinaze (asparaginase *Erwinia chrysanthemi*)

Background

Erwinaze (asparaginase *Erwinia chrysanthemi*) is an asparagine-specific enzyme.

L-asparaginase is a tetrameric enzyme consisting of four identical subunits, each having a molecular weight of about 35 kDa. Asparaginase *Erwinia chrysanthemi* catalyzes the deamidation of asparagine to aspartic acid and ammonia, resulting in a reduction in circulating levels of asparagine. The mechanism of action of Erwinaze is thought to be based on the inability of leukemic cells to synthesize asparagine due to lack of asparagine synthetase activity, resulting in cytotoxicity specific for leukemic cells that depend on an exogenous source of the amino acid asparagine for their protein metabolism and survival (1).

Erwinaze (asparaginase *Erwinia chrysanthemi*) is indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to *E. coli*-derived asparaginase as a component of a multi-agent chemotherapeutic regimen (1).

Regulatory Status

FDA-approved indication: Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to *E. coli*-derived asparaginase (1).

Erwinaze is contraindicated in patients with a history of pancreatitis, thrombosis, hemorrhagic events or anaphylaxis reaction with prior L-asparaginase therapy. Discontinue Erwinaze in the event of serious hypersensitivity reactions, including anaphylaxis, and severe or hemorrhagic

5.21.17

Section:	Prescription Drugs	Effective Date:	April 1, 2021
Subsection:	Antineoplastic Agents	Original Policy Date:	February 28, 2012
Subject:	Erwinaze	Page:	2 of 4

pancreatitis. Glucose intolerance can occur and, in some cases, may be irreversible. Perform appropriate monitoring and treat hyperglycemia with insulin, as necessary. If thrombosis or hemorrhage occurs discontinue Erwinaze until resolved. Use in pregnant women only if clearly needed. Do not use in lactating women (1).

Related policies

Asparlas, Oncaspar

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Erwinaze may be considered **medically necessary** for the treatment of patients with acute lymphoblastic leukemia (ALL) and if the conditions indicated below are met.

Erwinaze is considered **investigational** for all other indications.

Prior-Approval Requirements

Diagnosis

Patient must have the following:

1. Acute lymphoblastic leukemia (ALL)
 - a. Hypersensitivity to *E. coli*-derived asparaginase
 - b. Prescriber agrees to monitor bilirubin, liver function tests (LFTs), and glucose

Prior – Approval *Renewal* Requirements

Same as above

Policy Guidelines

Pre - PA Allowance

None

Section:	Prescription Drugs	Effective Date:	April 1, 2021
Subsection:	Antineoplastic Agents	Original Policy Date:	February 28, 2012
Subject:	Erwinaze	Page:	3 of 4

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Erwinaze (asparaginase *Erwinia chrysanthemi*) can be used as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to native or pegylated *Escherichia coli* (*E. coli*)-derived asparaginase. Erwinaze is contraindicated in patients with a history of pancreatitis, thrombosis, hemorrhagic events or anaphylaxis reaction with prior L-asparaginase therapy. Erwinaze therapy should be discontinued if the above conditions occur during therapy. Glucose intolerance could occur and may be irreversible (1).

Prior approval is required to ensure the safe, clinically appropriate and cost-effective use of Erwinaze while maintaining optimal therapeutic outcomes.

References

1. Erwinaze [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; December 2019.

Policy History

Date	Action
February 2012	New Policy
March 2013	Annual editorial and reference update
March 2014	Annual review
March 2015	Annual editorial review and reference update
June 2016	Annual editorial review and reference update Policy number changed from 5.04.17 to 5.21.17
June 2017	Annual review
June 2018	Annual editorial review
June 2019	Annual review
September 2019	Annual review. Added requirement to monitor bilirubin, LFTs, and glucose per FEP
June 2020	Annual review and reference update

5.21.17

Section:	Prescription Drugs	Effective Date:	April 1, 2021
Subsection:	Antineoplastic Agents	Original Policy Date:	February 28, 2012
Subject:	Erwinaze	Page:	4 of 4

March 2021 Annual review

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 12, 2021 and is effective on April 1, 2021.